Celldex Therapeutics (CLDX) Projected to Release Quarterly Earnings on Monday

Key Points

• Celldex Therapeutics is expected to report Q3 2026 results after Monday’s market close, with analysts forecasting a loss of $1.02 per share and revenue of $0.72 million.
• In its prior quarter, Celldex posted a smaller-than-expected loss of $0.94 per share, but revenue of $0.02 million fell well short of the $0.73 million consensus estimate.
• Analysts maintain a “Moderate Buy” consensus, with 11 Buy, one Hold and one Sell rating and an average price target of $63.08, versus the stock’s recent price of $29.93.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) is expected to be releasing its Q3 2026 results after the market closes on Monday, November 9th. Analysts expect Celldex Therapeutics to post earnings of ($1.02) per share and revenue of $0.72 million for the quarter. Interested persons can find conference call details on the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Monday, November 9, 2026 at 4:00 PM ET.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last released its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.94) earnings per share for the quarter, beating the consensus estimate of ($1.06) by $0.12. The firm had revenue of $0.02 million during the quarter, compared to analysts' expectations of $0.73 million. On average, analysts expect Celldex Therapeutics to post ($4.17) EPS for the current fiscal year and ($4.29) EPS for the next fiscal year.

Celldex Therapeutics Trading Down 0.6%

NASDAQ:CLDX opened at $29.93 on Monday. Celldex Therapeutics has a twelve month low of $22.10 and a twelve month high of $45.14. The company has a market cap of $2.35 billion, a P/E ratio of -6.92 and a beta of 1.04. The company's 50-day moving average price is $34.06 and its 200-day moving average price is $32.58.

Analyst Ratings Changes

A number of research firms have commented on CLDX. Wall Street Zen upgraded Celldex Therapeutics from a "strong sell" rating to a "sell" rating in a research report on Sunday, July 12th. Guggenheim upped their price target on Celldex Therapeutics from $90.00 to $100.00 and gave the company a "buy" rating in a report on Monday, July 20th. Cantor Fitzgerald lifted their price target on Celldex Therapeutics from $61.00 to $72.00 and gave the stock an "overweight" rating in a research report on Tuesday, September 22nd. Wells Fargo & Company lifted their target price on Celldex Therapeutics from $48.00 to $72.00 and gave the company an "overweight" rating in a research note on Wednesday, July 29th. Finally, Barclays raised their target price on Celldex Therapeutics from $48.00 to $53.00 and gave the company an "overweight" rating in a report on Friday, August 7th. Eleven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $63.08.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing targeted therapeutics for diseases with significant unmet medical needs. The company uses antibody-based technologies to develop treatments intended to modulate the immune system and address inflammatory, autoimmune and other serious conditions.

Celldex's lead investigational product is barzolvolimab, an antibody designed to selectively block the KIT receptor and reduce mast-cell activity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.